CTRP3 and Progranulin in Patients With Coronary Artery Disease

August 31, 2020 updated by: Kyung Mook Choi, Korea University

Implications of C1q/TNF-related Protein-3(CTRP-3) and Progranulin in Patients With Acutecoronary Syndrome and Stable Angina Pectoris

Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (CVD). Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors.

Study Overview

Status

Completed

Conditions

Detailed Description

CTRP-3 (synonyms CORS-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. Using a recently developed enzymelinked immunosorbent assay (ELISA), we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation.

Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.

Study Type

Observational

Enrollment (Actual)

362

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
      • Seoul, Korea, Republic of
        • Korea University Guro Hospital Dept. of Endocrinology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Acute coronary syndrome (ACS) patients, who were admitted to the coronary care units of the Division of Cardiology at Guro Hospital in Korea University Medical Center.

Control subjects were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.

Description

Inclusion Criteria:

  • acute myocardial infarction
  • unstable angina
  • stable angina pectoris

Exclusion Criteria:

For control group, we exclude the participants who had

  • a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
  • type 2 diabetes
  • stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
  • malignancy
  • severe renal or hepatic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Acute coronary syndrome (ACS)
Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
Stable angina pectoris (SAP)
Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
Control
Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CTRP3
Time Frame: 16 months
CTRP3 (ng/ml)
16 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SBP
Time Frame: 16 months
SBP (mmHg)
16 months
LDL cholesterol
Time Frame: 16 months
LDL (mg/dl)
16 months
hsCRP
Time Frame: 16 months
hsCRP (mg/dl)
16 months
creatinine
Time Frame: 16 months
creatinine (mg/dl)
16 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Korea University

Investigators

  • Principal Investigator: Kyung Mook Choi, M.D., Korea University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2011

Primary Completion (Actual)

December 31, 2012

Study Completion (Actual)

December 31, 2012

Study Registration Dates

First Submitted

June 2, 2013

First Submitted That Met QC Criteria

June 2, 2013

First Posted (Estimate)

June 5, 2013

Study Record Updates

Last Update Posted (Actual)

September 2, 2020

Last Update Submitted That Met QC Criteria

August 31, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAD(CTRP3,PRGL)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe